aspirin © fanelie rosier - istockphoto

'cubed' webzine

Anti-allergy parasite
Pancreas protector
Pop hit detector
Body Sensitive Cancer Treatment
Cheaper Smarter phones
Sports Training Tool
Light energy harvesting
Kitchen sink French
Clever cameras
Catalytic clothing
Smart surveillance
Super Broccoli
Kick and click
Pico secure access
Smartphone in Orbit
3D printed plane
Transmitting Data With Light
Brain cell bank
Energy for all seasons
Life-Saving Frogs
Dolphin Therapy
Rainbow money
In a Heartbeat
Restoring Speech
Safer Mosquitoes
Visualising Landscape Changes
Drumming Denim
Genetic clues for Alzheimer’s
Shower-Powered Radio
Assisted-Living Home
Fast-Scan Security
Keeping The Beat
Starfish non-stick drugs
Common Drug Could Reduce Cancer Risk
The Carbon Planet
3D Movie Tool
New Skin for Buildings
Pole Vaulting Pterosaurs
Bees Solve Problem
Rubber Tree Breakthrough
The Camouflage of Cats
Spotting PTSD
Spray on Clothes
The Biology of Thinking
Sphere TV
Driverless bus
Virtual London

Oxford University’s Department of Clinical Neurology

For information on research at Oxford University’s Department of Clinical Neurology

University of Edinburgh

For more information on cancer research at the University of Edinburgh

cubed logo © British Council

Common drug could reduce cancer risk

Data from the 1970s
A new study by scientists from Oxford, Edinburgh, London and Japan shows that at low doses, aspirin can significantly reduce the risk of a range of cancers. Professor Peter Rothwell of the Department of Clinical Neurology at Oxford University, who led the work, prescribed aspirin for many years to patients with minor strokes and was interested in other possible effects. ‘There is some data going back to the 1970s,’ explains Professor Rothwell, ‘suggesting that aspirin might have an effect on growth development of cancers in the laboratory cell cultures, and in animal models of cancer.’ There was also some supporting observational data in humans. But the problem with lab data is that the effect on animals isn’t necessarily the same as humans. And observational data isn’t always reliable. Professor Rothwell gives the example of studies of Hormone Replacement Therapy which suggested that HRT prevented heart attacks and strokes in middle aged women, but subsequent trials showed the studies were biased.

Proof-of-principle
So the team followed up aspirin trials on heart attacks and strokes from the 1980s and 1990s. They looked at whether there was a difference in cancer rates 20 and 30 years on. ‘We originally looked at some of the high dose aspirin trials and showed that aspirin definitely prevented colon and rectal cancer. Useful proof-of-principle but not particularly clinically useful, so we showed in a paper a couple of months ago in The Lancet that low dose aspirin also prevented colon and rectal cancers. This suggested that low dose aspirin may also prevent other cancers and that led to the next paper.’

cancer cell © Sebastian Kaulitzki - iStockphoto

Lasting benefit
The data suggests a lasting benefit of taking aspirin. People who had taken aspirin for a period had 20 per cent lower risk of death from certain types of cancer and 35 per cent lower for gastrointestinal cancers. ‘We know from the trials of aspirin looking at heart attacks and strokes that there is a small benefit from aspirin in helping middle-aged people in terms of preventing heart attacks and strokes. That’s partly offset by the risk of stomach bleeding, but there is still some benefit. When you add in the cancer benefit on top of that it pushes things much more in favour.’

LearnEnglish Science activities
Why not do a language activity based on this cubed story, Common drug could reduce cancer risk? You can double-click on any word on this page for a dictionary definition.

DCSIMG